• Home
  •  / Selecta Biosciences

Selecta Biosciences

OverviewSuggest Edit

Selecta Biosciences is a clinical-stage biopharmaceutical company using its synthetic vaccine particle, or SVP, technology to discover and develop targeted therapies that are designed to modulate the immune system to effectively and safely treat rare and serious diseases. The Company's SVP technology is capable of incorporating a wide range of antigens and immunomodulators, potentially allowing for the development of products that either induce antigen-specific immune tolerance or activate the immune system. It encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of ADAs in response to life-sustaining biologic drugs. Selecta Biosciences' lead product candidate, SEL-212, is a combination of a therapeutic enzyme and our SVP technology that is designed to be the first biologic treatment that durably controls uric acid in refractory gout and dissolves and removes the harmful deposits of uric acid in chronic tophaceous gout, both of which are painful and debilitating rare diseases with an unmet medical need. 

TypePublic
Founded2008
HQWatertown, MA, USMap
Websiteselectabio.com
Employee Ratings3.6More
Overall CultureFMore
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Jan 2019)39(-39%)
Revenue (FY, 2019)$6.7 M(-17%)
Share Price (Jan 2021)$3.5 (-3%)
Cybersecurity ratingCMore

Key People/Management at Selecta Biosciences

Carsten Brunn

Carsten Brunn

President and CEO
Carrie S. Cox

Carrie S. Cox

Chairman
Brad Dahms

Brad Dahms

Chief Financial Officer
Timothy Barabe

Timothy Barabe

Director
Lloyd Johnston

Lloyd Johnston

Chief Operating Officer
Scott D. Myers

Scott D. Myers

Director
Show more

Selecta Biosciences Office Locations

Selecta Biosciences has an office in Watertown
Watertown, MA, US (HQ)
65 Grove St
Show all (1)

Selecta Biosciences Financials and Metrics

Selecta Biosciences Revenue

Selecta Biosciences's revenue was reported to be $6.68 m in FY, 2019
USD

Revenue (Q3, 2020)

4.6m

Net income (Q3, 2020)

(9.7m)

EBIT (Q3, 2020)

(13.7m)

Market capitalization (15-Jan-2021)

383.5m

Closing stock price (15-Jan-2021)

3.5

Cash (30-Sept-2020)

146.3m

EV

272.6m
Selecta Biosciences's current market capitalization is $383.5 m.
Annual
USDFY, 2016FY, 2019

Revenue

8.1m6.7m

General and administrative expense

13.1m16.4m

R&D expense

29.7m42.7m

Operating expense total

42.8m59.1m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q4, 2017Q1, 2018Q2, 2018Q3, 2018Q4, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

2.0m1.0m137.0k26.0k27.0k207.0k903.0k10.0k13.0k4.6m

General and administrative expense

2.4m2.5m3.9m4.9m4.4m18.8m4.7m4.4m4.1m18.2m4.5m4.1m3.7m4.1m5.6m4.4m

R&D expense

6.0m6.0m11.0m11.0m9.5m45.2m11.1m14.4m11.9m47.7m7.4m12.1m8.1m14.7m10.7m14.0m

Operating expense total

8.4m8.5m14.9m15.9m13.9m64.0m15.8m18.8m15.9m65.9m11.9m16.2m11.8m18.8m16.4m18.4m
show all
Annual
USDFY, 2016FY, 2019

Cash

58.7m89.9m

Accounts Receivable

215.0k5.0m

Prepaid Expenses

1.5m

Inventories

2.4m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q4, 2017Q1, 2018Q2, 2018Q3, 2018Q4, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

82.6m59.5m26.6m82.6m72.2m70.6m58.2m60.2m50.5m37.4m32.2m30.2m34.2m72.6m59.7m146.3m

Accounts Receivable

2.0m483.0k63.0k1.0k63.0k52.0k12.6m

Prepaid Expenses

2.1m3.3m2.8m1.8m2.9m2.0m1.8m2.6m5.1m4.7m10.8m2.5m1.6m1.6m1.0m7.6m

Current Assets

89.0m83.4m71.5m114.6m107.4m98.7m85.0m68.8m55.6m42.1m59.5m44.4m36.1m74.4m61.1m166.5m
show all
Annual
USDFY, 2016FY, 2019

Net Income

(36.2m)(55.3m)

Depreciation and Amortization

802.0k726.0k

Accounts Payable

2.7m(600.0k)

Cash From Operating Activities

(19.7m)(51.4m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q4, 2017Q1, 2018Q2, 2018Q3, 2018Q4, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(14.4m)(22.1m)(15.1m)(31.1m)(45.8m)(65.3m)(15.9m)(34.7m)(50.7m)(65.3m)(12.1m)(28.5m)(40.5m)(19.6m)(43.7m)(53.4m)

Depreciation and Amortization

364.0k386.0k567.0k750.0k169.0k584.0k975.0k522.0k

Accounts Payable

(338.0k)(35.0k)(2.6m)(2.3m)(2.4m)(2.3m)180.0k155.0k(369.0k)(516.0k)(407.0k)1.4m378.0k836.0k735.0k(29.0k)

Cash From Operating Activities

(15.8m)(21.2m)(15.3m)(23.9m)(39.4m)(52.0m)(13.4m)(30.4m)(46.4m)(59.2m)(20.2m)(27.4m)(38.6m)(11.7m)(23.5m)42.1m
show all
USDQ2, 2016

Financial Leverage

1.3 x
Show all financial metrics

Selecta Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

Learn more about our premium products
SecurityScorecard logo

Selecta Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

Learn more about our premium products
CSRHub logo

Selecta Biosciences Online and Social Media Presence

Selecta Biosciences's Trends

Embed Graph

Selecta Biosciences Company Culture

  • Overall Culture

    F

    50/100

  • CEO Rating

    F

    50/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Selecta Biosciences News and Updates

January 06, 2021

Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy

- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8 alone –
January 04, 2021

Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference

WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Exec…
November 19, 2020

AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia

Gene therapy MMA-101 has obtained both orphan drug designation and rare pediatric disease designation from the FDA Gene therapy MMA-101 has obtained both orphan drug designation and rare pediatric disease designation from the FDA
October 29, 2020

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights

WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to host a con…
October 20, 2020

Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia

WATERTOWN, Mass., and Research Triangle Park, N.C., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MMA-101 for t…
October 16, 2020

Thinking about buying stock in Rewalk Robotics, Selecta Biosciences, Aphria, Plug Power, or Aslan Pharmaceuticals?

NEW YORK, Oct. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RWLK, SELB, APHA, PLUG, and ASLN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Selecta Biosciences Blogs

January 06, 2021

Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTOR™ Platform in Gene Therapy

Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTOR™ Platform in Gene Therapy Lorraine.Chua@… Wed, 01/06/2021 - 08:01 Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits …
November 05, 2020

Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates Content Import Thu, 11/05/2020 - 07:31 Selecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates Nov 05, 2020 This release is …
October 08, 2020

Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy

Application of ImmTOR™  plus IGAN’s IgA p rotease to target   immunoglobulin A ( IgA ) deposition, the critical event leading to IgA N ephropathy ( IgAN ) Selecta’s IgA nephropathy program builds upon SEL-212 , which has demonstrated ImmTOR™   e ffective at tolerizing a highly immunogenic
September 30, 2020

Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Supporting the Potential for Important Clinical Improvement in Patients with Chronic Refractory Gout

All data consistent with stronger performance   of SEL-212 versus pegloticase N umerically higher response rate for SEL-212 versus pegloticase during primary endpoint of months 3 and 6 combined ;   s tatistically significant higher response rate for SEL-212 versus pegloticase during month 3
September 01, 2020

Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank

Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank Content Import Tue, 09/01/2020 - 08:01 Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank Sep 01, 2020 …
August 03, 2020

Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer

WATERTOWN, Mass. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced the appointment of Peter G.
Show more

 Selecta Biosciences Frequently Asked Questions

  • When was Selecta Biosciences founded?

    Selecta Biosciences was founded in 2008.

  • Who are Selecta Biosciences key executives?

    Selecta Biosciences's key executives are Carsten Brunn, Carrie S. Cox and Brad Dahms.

  • How many employees does Selecta Biosciences have?

    Selecta Biosciences has 39 employees.

  • What is Selecta Biosciences revenue?

    Latest Selecta Biosciences annual revenue is $6.7 m.

  • What is Selecta Biosciences revenue per employee?

    Latest Selecta Biosciences revenue per employee is $171.2 k.

  • Who are Selecta Biosciences competitors?

    Competitors of Selecta Biosciences include Seed Health, Biogen and MyoKardia.

  • Where is Selecta Biosciences headquarters?

    Selecta Biosciences headquarters is located at 65 Grove St, Watertown.

  • Where are Selecta Biosciences offices?

    Selecta Biosciences has an office in Watertown.

  • How many offices does Selecta Biosciences have?

    Selecta Biosciences has 1 office.